Question 1

What are the specific treatments I would receive if I participate in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant clinical trial (NCT01941680). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my response to treatment be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant clinical trial (NCT01941680). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of Zidovudine and Pegylated Interferon?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant clinical trial (NCT01941680). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I do not respond well to the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant clinical trial (NCT01941680). Contact the study team or your healthcare provider for specific answers.

Question 5

How does this trial compare to other treatment options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant clinical trial (NCT01941680). Contact the study team or your healthcare provider for specific answers.

Question 6

What are the logistics of participating, such as visit frequency and duration?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant clinical trial (NCT01941680). Contact the study team or your healthcare provider for specific answers.

What this study is about